文献速递甲状腺与颈部外科

超快速术中甲状旁腺激素监测系统:前瞻性、多中心临床有效性研究

Ultrafast intraoperative parathyroid hormone monitoring system: prospective, multicentre, clinical validity study.
PubMed 文献 · Br J Surg · 2024-01-01

这项前瞻性多中心研究评估了可在5分钟内测量全血甲状旁腺激素(PTH)的NBCL CONNECT分析仪。234例原发性甲状旁腺功能亢进症患者接受甲状旁腺切除术,分析仪预测生化治愈的敏感性、特异性和总体准确率在三个阶段逐步提升,第三阶段分别为98.6%、100%和98.6%,无假阳性结果。

要点

  • 分析仪5分钟测全血PTH,第三阶段预测生化治愈敏感性98.6%、特异性100%、准确率98.6%。
  • 与Roche平台相关性很强(R=0.92-0.98,P<0.001),与Abbott平台相关性强(R=0.82-0.91,P<0.001)。
  • 更严格的采样方案和凝块检测系统改进减少了凝块样本和假阴性结果。

核心结论

  • 甲状旁腺手术中术中PTH监测可使用该分析仪在全血中准确、简便且快速地完成。

研究设计与样本

  • 前瞻性多中心研究,分阶段进行:结果回顾、建议以及机械设计、卡盒组件、校准和采样方案的改进实施。
  • 共234例患者(55例男性,179例女性)接受甲状旁腺切除术,中位年龄58.5岁(全距15-88岁)。
  • 手术方式包括195例微创手术、38例双侧颈部探查、1例胸腔镜手术,12例中转。
  • 研究时间为2021年11月至2022年7月。

主要发现

  • 225例(96.2%)原发性甲状旁腺功能亢进症治愈。
  • 分析仪检测预测生化治愈的敏感性、特异性和总体准确率:第一阶段83.9%、100%和84.8%;第二阶段91.2%、100%和91.3%;第三阶段98.6%、100%和98.6%。
  • 无假阳性结果(阳性预测值100%)。
  • 分析仪测量值与Roche设备测量值相关性很强(第一阶段R=0.98,P<0.001;第二阶段R=0.92,P<0.001;第三阶段R=0.94,P<0.001),与Abbott平台测量值相关性强(R=0.82,P<0.001;R=0.89,P<0.001;R=0.91,P<0.001)。
  • 引入更严格的采样方案和凝块检测系统改进后,凝块样本数和假阴性结果减少;由护士或实验室人员操作测量对结果无影响。

关键数值与推荐

  • 术中采用Miami标准,即PTH浓度下降50%定义为生化治愈;术后血钙正常定义原发性甲状旁腺功能亢进症治愈。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraoperative parathyroid hormone (PTH) monitoring is a proven and reliable adjunct to parathyroid surgery, able to improve the outcomes and efficiency of the diagnostic and therapeutic pathway for patients with primary hyperparathyroidism. This study evaluated the innovative, compact, fully automated NBCL CONNECT Analyzer, which can measure whole-blood PTH in 5 min. METHODS: A prospective multicentre study was conducted in stages: results reviews, recommendations, and implementation of improvements to the mechanical design, components of cartridges, calibration, and sampling protocols. Patients undergoing parathyroidectomy had PTH levels measured on the Analyzer and main laboratory platforms, either Roche or Abbott. The Miami criterion of a 50% drop in PTH concentration was used to define biochemical cure during surgery, and normal postoperative calcium level as cure of primary hyperparathyroidism. Measurements on the Analyzer were done by laboratory staff in London and nurses in Stuttgart. The Pearson coefficient (R) and Wilcoxon test were used for statistical analysis. RESULTS: Some 234 patients (55 male, 179 female) with a median age of 58.5 (age full range 15-88) years underwent parathyroidectomy (195 minimally invasive, 38 bilateral neck exploration, 1 thoracoscopic; 12 conversions) for primary hyperparathyroidism between November 2021 and July 2022. Primary hyperparathyroidism was cured in 225 patients (96.2%). The sensitivity, specificity, and overall accuracy of the Analyzer assay in predicting biochemical cure were 83.9, 100, and 84.8% in phase 1; 91.2, 100, and 91.3% in phase 2; and 98.6, 100, and 98.6% in phase 3. There were no false-positive results (positive predictive value 100%). Correlations between Analyzer measurements and those obtained using the Roche device were very strong (R = 0.98, P < 0.001 in phase 1; R = 0.92, P < 0.001 in phase 2; R = 0.94, P < 0.001 in phase 3), and correlations for Analyzer readings versus those from the Abbott platform were strong (R = 0.82, P < 0.001; R = 0.89, P < 0.001; R = 0.91, P < 0.001). The Analyzer showed continued good mechanical performance, with stable and repeatable operations (calibrations, quality controls). Introducing a stricter sampling protocol and improvements in the clot-detecting system led to a decrease in the number of clotted samples and false-negative results. Outcomes were not affected by measurements performed either by nurses or laboratory staff. CONCLUSION: Intraoperative PTH monitoring during parathyroid surgery can be done accurately, simply, and quickly in whole blood using the Analyzer.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Kurzawinski TR, Zielke A, Busch M, et al. Ultrafast intraoperative parathyroid hormone monitoring system: prospective, multicentre, clinical validity study. Br J Surg. 2024. PMID: 38713606. doi:10.1093/bjs/znae101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。